Sac-TMT in Salivary Gland Cancers
NCT07928193, Phase 2, Not yet recruiting, Latin American Cooperative Oncology Group
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Sac-TMT in Salivary Gland Cancers | ClinicalTrials.gov |
| NCT number | NCT07928193 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Phase 2 | ClinicalTrials.gov |
| Enrollment | 64 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Latin American Cooperative Oncology Group | ClinicalTrials.gov |
| Conditions | Salivary Gland Cancers, Adenoid Cystic Carcinoma of the Salivary Gland | ClinicalTrials.gov |
| Interventions | Sacituzumab Tirumotecan (Sac-TMT) | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Objective Response Rate (ORR) in Cohort 1 (ACC) | Up to 12 cycles (approximately 12 months). | Proportion of participants with a best overall response of complete response (CR) or partial response (PR) as determined by RECIST 1.1 in the Adenoid Cystic Carcinoma cohort. | ClinicalTrials.gov |
| Primary | Objective Response Rate (ORR) in Cohort 2 (Non-ACC) | Up to 12 cycles (approximately 12 months). | Proportion of participants with a best overall response of complete response (CR) or partial response (PR) as determined by RECIST 1.1 in the Non-Adenoid Cystic Carcinoma cohort. | ClinicalTrials.gov |
| Secondary | Objective Response Rate by Independent Central Review (ORR-ICR) | From enrollment through disease progression or end of treatment, assessed up to 12 cycles (approximately 12 months). | Percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR) as determined by an Independent Central Review (ICR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). | ClinicalTrials.gov |
| Secondary | Disease Control Rate (DCR) | From enrollment through disease progression or end of treatment, assessed up to 12 cycles (approximately 12 months). | Percentage of participants with a best overall response of complete response (CR), partial response (PR), or stable disease (SD) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). | ClinicalTrials.gov |
| Secondary | Duration of Response (DoR) | From first documented response until disease progression or death, assessed up to 40 months. | Time from the first documented objective response (complete response \[CR\] or partial response \[PR\]) to the date of first documented disease progression according to RECIST v1.1 or death due to any cause, evaluated in responders only. | ClinicalTrials.gov |
| Secondary | Progression-Free Survival (PFS) | From treatment initiation until disease progression or death, assessed up to 40 months. | Time from treatment initiation to first documented disease progression according to RECIST v1.1 (as evaluated by investigator assessment) or death due to any cause, whichever occurs first. | ClinicalTrials.gov |
| Secondary | 6-Month Progression-Free Survival (6-Month PFS) | At 6 months. | Percentage of participants alive and progression-free at 6 months after enrollment according to RECIST v1.1, estimated using the Kaplan-Meier method. | ClinicalTrials.gov |
| Secondary | 12-Month Progression-Free Survival (12-Month PFS) | At 12 months. | Percentage of participants alive and progression-free at 12 months after enrollment according to RECIST v1.1, estimated using the Kaplan-Meier method. | ClinicalTrials.gov |
| Secondary | Overall Survival (OS) | From treatment initiation until death, assessed up to 40 months. | Time from treatment initiation to death from any cause. | ClinicalTrials.gov |
| Secondary | Incidence of Treatment-Emergent Adverse Events (TEAEs) | From baseline through 30 days after the last dose of study treatment (approximately 13 months). | Number of participants with treatment-emergent adverse events (TEAEs) of any grade and Grade 3 or higher, characterized and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0). | ClinicalTrials.gov |
| Secondary | Change From Baseline in Health-Related Quality of Life Using EORTC QLQ-C30 | Baseline, every 6 weeks up to 24 weeks. | Assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The questionnaire includes functional scales, symptom scales, and a global health status/QoL scale. All domain and item scores are linearly transformed to a 0 to 100 scale. For functional scales and global health status, higher scores represent better quality of life and higher level of functioning. For symptom scales, higher scores represent greater symptom burden/severity. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)